Literature DB >> 29078283

Humanized mouse model supports development, function, and tissue residency of human natural killer cells.

Dietmar Herndler-Brandstetter1, Liang Shan1, Yi Yao2, Carmen Stecher1, Valerie Plajer1, Melanie Lietzenmayer1, Till Strowig1, Marcel R de Zoete1, Noah W Palm1, Jie Chen1, Catherine A Blish3, Davor Frleta4, Cagan Gurer4, Lynn E Macdonald4, Andrew J Murphy4, George D Yancopoulos4, Ruth R Montgomery2, Richard A Flavell5,6.   

Abstract

Immunodeficient mice reconstituted with a human immune system represent a promising tool for translational research as they may allow modeling and therapy of human diseases in vivo. However, insufficient development and function of human natural killer (NK) cells and T cell subsets limit the applicability of humanized mice for studying cancer biology and therapy. Here, we describe a human interleukin 15 (IL15) and human signal regulatory protein alpha (SIRPA) knock-in mouse on a Rag2-/- Il2rg-/- background (SRG-15). Transplantation of human hematopoietic stem and progenitor cells into SRG-15 mice dramatically improved the development and functional maturation of circulating and tissue-resident human NK and CD8+ T cells and promoted the development of tissue-resident innate lymphoid cell (ILC) subsets. Profiling of human NK cell subsets by mass cytometry revealed a highly similar expression pattern of killer inhibitory receptors and other candidate molecules in NK cell subpopulations between SRG-15 mice and humans. In contrast to nonobese diabetic severe combined immunodeficient Il2rg-/- (NSG) mice, human NK cells in SRG-15 mice did not require preactivation but infiltrated a Burkitt's lymphoma xenograft and efficiently inhibited tumor growth following treatment with the therapeutic antibody rituximab. Our humanized mouse model may thus be useful for preclinical testing of novel human NK cell-targeted and combinatory cancer immunotherapies and for studying how they elicit human antitumor immune responses in vivo. Published under the PNAS license.

Entities:  

Keywords:  IL-15; ILC; NK cells; cancer immunotherapy; humanized mice

Mesh:

Substances:

Year:  2017        PMID: 29078283      PMCID: PMC5692533          DOI: 10.1073/pnas.1705301114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

2.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment.

Authors:  Takuji Yamauchi; Katsuto Takenaka; Shingo Urata; Takahiro Shima; Yoshikane Kikushige; Takahito Tokuyama; Chika Iwamoto; Mariko Nishihara; Hiromi Iwasaki; Toshihiro Miyamoto; Nakayuki Honma; Miki Nakao; Takashi Matozaki; Koichi Akashi
Journal:  Blood       Date:  2013-01-04       Impact factor: 22.113

4.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

5.  Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse.

Authors:  Ikumi Katano; Takeshi Takahashi; Ryoji Ito; Tsutomu Kamisako; Takuma Mizusawa; Yuyo Ka; Tomoyuki Ogura; Hiroshi Suemizu; Yutaka Kawakami; Mamoru Ito
Journal:  J Immunol       Date:  2015-02-23       Impact factor: 5.422

6.  Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells.

Authors:  Maya C André; Annika Erbacher; Christian Gille; Vanessa Schmauke; Barbara Goecke; Alexander Hohberger; Philippa Mang; Ayline Wilhelm; Ingo Mueller; Wolfgang Herr; Peter Lang; Rupert Handgretinger; Udo F Hartwig
Journal:  J Immunol       Date:  2010-07-28       Impact factor: 5.422

7.  IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.

Authors:  Yumeng Mao; Vincent van Hoef; Xiaonan Zhang; Erik Wennerberg; Julie Lorent; Kristina Witt; Laia Masvidal; Shuo Liang; Shannon Murray; Ola Larsson; Rolf Kiessling; Andreas Lundqvist
Journal:  Blood       Date:  2016-07-27       Impact factor: 22.113

8.  Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets.

Authors:  Taheri Sathaliyawala; Masaru Kubota; Naomi Yudanin; Damian Turner; Philip Camp; Joseph J C Thome; Kara L Bickham; Harvey Lerner; Michael Goldstein; Megan Sykes; Tomoaki Kato; Donna L Farber
Journal:  Immunity       Date:  2012-12-20       Impact factor: 31.745

Review 9.  Human hemato-lymphoid system mice: current use and future potential for medicine.

Authors:  Richard A Flavell; Markus G Manz; Anthony Rongvaux; Hitoshi Takizawa; Till Strowig; Tim Willinger; Elizabeth E Eynon
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

10.  Graft versus host disease in the bone marrow, liver and thymus humanized mouse model.

Authors:  Matthew B Greenblatt; Vladimir Vrbanac; Vladimir Vbranac; Trevor Tivey; Kelly Tsang; Andrew M Tager; Antonios O Aliprantis
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more
  63 in total

1.  Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models.

Authors:  Trisha R Sippel; Stefan Radtke; Tayla M Olsen; Hans-Peter Kiem; Anthony Rongvaux
Journal:  Blood Adv       Date:  2019-02-12

Review 2.  Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice.

Authors:  Yoriko Saito; Leonard D Shultz; Fumihiko Ishikawa
Journal:  Trends Immunol       Date:  2020-07-03       Impact factor: 16.687

Review 3.  Humanized mouse model: a review on preclinical applications for cancer immunotherapy.

Authors:  Ling Yin; Xue-Jing Wang; De-Xi Chen; Xiao-Ni Liu; Xiao-Jun Wang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

4.  Profiling of the Human Natural Killer Cell Receptor-Ligand Repertoire.

Authors:  Elena Vendrame; Julia L McKechnie; Thanmayi Ranganath; Nancy Q Zhao; Arjun Rustagi; Rosemary Vergara; Geoffrey T Ivison; Lisa M Kronstad; Laura J Simpson; Catherine A Blish
Journal:  J Vis Exp       Date:  2020-11-19       Impact factor: 1.355

Review 5.  Humanized mouse models of immunological diseases and precision medicine.

Authors:  Leonard D Shultz; James Keck; Lisa Burzenski; Sonal Jangalwe; Shantashri Vaidya; Dale L Greiner; Michael A Brehm
Journal:  Mamm Genome       Date:  2019-03-07       Impact factor: 2.957

Review 6.  Humanized mouse models of genetic immune disorders and hematological malignancies.

Authors:  Rajeev K Tyagi; Jing Li; Justin Jacobse; Scott B Snapper; Dror S Shouval; Jeremy A Goettel
Journal:  Biochem Pharmacol       Date:  2019-10-18       Impact factor: 5.858

7.  Humanized mouse models reveal an immunologic classification of idiopathic CD4 lymphocytopenia subtypes.

Authors:  Ainhoa Perez-Diez; Xiangdong Liu; Virginia Sheikh; Gregg Roby; David F Stroncek; Irini Sereti
Journal:  JCI Insight       Date:  2019-07-25

Review 8.  Zebrafish patient avatars in cancer biology and precision cancer therapy.

Authors:  Maurizio Fazio; Julien Ablain; Yan Chuan; David M Langenau; Leonard I Zon
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

9.  Genome-wide analyses and functional profiling of human NK cell lines.

Authors:  Justin T Gunesch; Laura S Angelo; Sanjana Mahapatra; Raquel P Deering; Johanna E Kowalko; Patrick Sleiman; John W Tobias; Linda Monaco-Shawver; Jordan S Orange; Emily M Mace
Journal:  Mol Immunol       Date:  2018-07-24       Impact factor: 4.407

10.  Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.

Authors:  Nan Guo Ring; Dietmar Herndler-Brandstetter; Kipp Weiskopf; Liang Shan; Jens-Peter Volkmer; Benson M George; Melanie Lietzenmayer; Kelly M McKenna; Tejaswitha J Naik; Aaron McCarty; Yunjiang Zheng; Aaron M Ring; Richard A Flavell; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.